Effect of ?Selenium on controlling clinical symptoms in rheumatoid arthritis Patients

Evaluating the effects of oral Selenium as a adjuvant therapy on controling clinical symptoms in rhumatoid arthritis Patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20161204031229N4

Enrollment

Registered

2021-07-17

Start date

2021-08-17

Completion date

Unknown

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis. Rheumatoid arthritis, unspecified

Interventions

Intervention 1: Intervention group: Standard regimen plus selenium 200 µg twice daily for 12 months. Intervention 2: Control group: Standard regimen without selenium.

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Active disease at the time of enrollment Stable renal function No liver dysfunction Ability to receive oral medication

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Assessment of clinical symptoms. Timepoint: Before studying, after 12 months. Method of measurement: Disease Activity Score, version 28 questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAzade Eshraghi

Iran University of Medical Sciences

eshraghi.a@iums.ac.ir+98 21 8670 2030

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026